Free Trial Information
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc....
Read More
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc....
Read More
BioCentury | Mar 23, 2017
Financial News

Northwest Biotherapeutics completes private placement

...On March 17, cancer vaccine company Northwest Biotherapeutics Inc. (OTCQB:NWBO) raised $7.5 million through the sale of 28.8...
...21.6 million shares at $1. H.C. Wainwright was the placement agent. Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Alicia Parker Northwest Biotherapeutics Inc....
Read More
BioCentury | Feb 8, 2017
Clinical News

DCVax-L: Ph III ongoing

...last 17 of the planned 348 patients in the trial (see BioCentury, Jan. 9 ). Northwest Biotherapeutics Inc....
...PFS); overall survival (OS) and time to disease progression Status: Phase III ongoing Milestone: NA Julian Zhu DCVax-Brain DCVax-L Northwest Biotherapeutics Inc....
Read More
BioCentury | Jan 5, 2017
Clinical News

DCVax-L: Ph III ongoing

...0, 10 and 20 and at weeks 8, 16, 32, 48, 72, 96 and 120. Northwest Biotherapeutics Inc....
...PFS); overall survival (OS) and time to disease progression Status: Phase III ongoing Milestone: NA Julian Zhu DCVax-Brain DCVax-L Northwest Biotherapeutics Inc....
Read More
BioCentury | Dec 28, 2016
Financial News

Northwest completes direct public offering

...million shares at $0.35. Chardan Capital Markets was the placement agent. Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Alicia Parker Northwest Biotherapeutics Inc....
Read More
BioCentury | Oct 31, 2016
Financial News

Northwest Biotherapeutics postpones direct public offering

...announced: 2016-10-27 Type: Direct public offering Placement agent: Roth Capital Partners Investor: Institutional investor Note: Northwest Biotherapeutics...
Read More
BioCentury | Jul 11, 2016
Financial News

Northwest Biotherapeutics completes private placement of common stock and warrants

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2016-07-05 Type: Private placement of common stock and warrants Raised: $3.7 million Shares: 7.4 million Price: $0.50 Shares after offering: 109.1 million Placement agent: Chardan...
Read More
BioCentury | Mar 7, 2016
Financial News

Northwest Biotherapeutics completes direct public offering

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2016-02-29 Type: Direct public offering Raised: $10 million Shares: 5.9 million Price: $1.70 Shares after offering: 101.7 million Placement agent: H.C. Wainwright Investor: Institutional investors...
Read More
BioCentury | Jan 4, 2016
Financial News

Northwest Biotherapeutics completes direct public offering

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2015-12-24 Type: Direct public offering Raised: $12.6 million Shares: 3.5 million Price: $3.60 Shares after offering: 95.9 million Placement agent: H.C. Wainwright Investor: Institutional investors...
Read More
Items per page:
1 - 10 of 145
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc....
Read More
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd. $95.0 Northwest Biotherapeutics Inc....
Read More
BioCentury | Mar 23, 2017
Financial News

Northwest Biotherapeutics completes private placement

...On March 17, cancer vaccine company Northwest Biotherapeutics Inc. (OTCQB:NWBO) raised $7.5 million through the sale of 28.8...
...21.6 million shares at $1. H.C. Wainwright was the placement agent. Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Alicia Parker Northwest Biotherapeutics Inc....
Read More
BioCentury | Feb 8, 2017
Clinical News

DCVax-L: Ph III ongoing

...last 17 of the planned 348 patients in the trial (see BioCentury, Jan. 9 ). Northwest Biotherapeutics Inc....
...PFS); overall survival (OS) and time to disease progression Status: Phase III ongoing Milestone: NA Julian Zhu DCVax-Brain DCVax-L Northwest Biotherapeutics Inc....
Read More
BioCentury | Jan 5, 2017
Clinical News

DCVax-L: Ph III ongoing

...0, 10 and 20 and at weeks 8, 16, 32, 48, 72, 96 and 120. Northwest Biotherapeutics Inc....
...PFS); overall survival (OS) and time to disease progression Status: Phase III ongoing Milestone: NA Julian Zhu DCVax-Brain DCVax-L Northwest Biotherapeutics Inc....
Read More
BioCentury | Dec 28, 2016
Financial News

Northwest completes direct public offering

...million shares at $0.35. Chardan Capital Markets was the placement agent. Northwest Biotherapeutics Inc. (OTCQB:NWBO), Bethesda, Md. Alicia Parker Northwest Biotherapeutics Inc....
Read More
BioCentury | Oct 31, 2016
Financial News

Northwest Biotherapeutics postpones direct public offering

...announced: 2016-10-27 Type: Direct public offering Placement agent: Roth Capital Partners Investor: Institutional investor Note: Northwest Biotherapeutics...
Read More
BioCentury | Jul 11, 2016
Financial News

Northwest Biotherapeutics completes private placement of common stock and warrants

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2016-07-05 Type: Private placement of common stock and warrants Raised: $3.7 million Shares: 7.4 million Price: $0.50 Shares after offering: 109.1 million Placement agent: Chardan...
Read More
BioCentury | Mar 7, 2016
Financial News

Northwest Biotherapeutics completes direct public offering

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2016-02-29 Type: Direct public offering Raised: $10 million Shares: 5.9 million Price: $1.70 Shares after offering: 101.7 million Placement agent: H.C. Wainwright Investor: Institutional investors...
Read More
BioCentury | Jan 4, 2016
Financial News

Northwest Biotherapeutics completes direct public offering

Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Business: Cancer Date completed: 2015-12-24 Type: Direct public offering Raised: $12.6 million Shares: 3.5 million Price: $3.60 Shares after offering: 95.9 million Placement agent: H.C. Wainwright Investor: Institutional investors...
Read More
Items per page:
1 - 10 of 145